MDS 2022 | Extending the efficacy of levodopa in patients with Parkinson’s disease

Torsten Falk, PhD, University of Arizona, Tuscon, AZ, describes potential strategies to enable long-term use of levodopa in patients with Parkinson’s disease and levodopa-induced dyskinesia. Administration via an intestinal gel infusion using a percutaneous pump can provide more stable dopaminergic stimulation and initial studies have demonstrated the efficacy of low-dose ketamine to in patients with levodopa-induced dyskinesia. Additional dopamine receptor agonists are also needed to provide alternatives to levodopa. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.